A phase 3 clinical trial finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema -- a rare, potentially life-threatening disorder.
from Latest Science News -- ScienceDaily https://ift.tt/2E0NpZL
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment